VNS-REHAB At-Home - Post-Market Study for Using the Vivistim System® at Home

Recruiting

• Conditions: Ischemic Stroke; Upper Extremity Problem
• Interventions: Device: Vivistim System

• Registration Number: NCT05691023
• Lead Sponsor: MicroTransponder Inc.

Brief Summary

This is a single-arm post-market study of up to 150 participants, using up to 50 mobile therapists to conduct up to 36-hours at-home therapy. The study will assess at-home therapy implementation instead of an in-clinic therapy implementation for patients who are commercially implanted with the Vivistim System. Patients will be consented for eligibility if appropriate to be implanted with the Vivistim System per the indications for use (The MicroTransponder® Vivistim® Paired VNS™ System is intended to be used to stimulate the vagus nerve during rehabilitation therapy in order to reduce upper extremity motor deficits and improve motor function in chronic ischemic stroke patients with moderate to severe arm impairment.). Study participation includes receiving rehabilitation therapy paired with VNS, provided at the patient's home by a therapist, along with self-activated VNS. All subjects will be commercially implanted with the Vivistim System® after an ischemic stroke prior to Study treatment, although they may be consented prior to implant. It should be noted that the implant surgery is not part of the study.

Detailed Description

This study has two distinct stages: Stage I (Acute), a treatment period of up to 18-weeks of Paired VNS™ for upper limb motor deficits - where patients receive VNS Paired with rehabilitation - provided at-home by a therapist along with self-activated VNS home-therapy on remaining days; Stage II (Long-term), a follow-up period of up to two years during which subjects continue self-activated VNS at-home using a magnet during therapist-prescribed functional tasks. The at-home therapy is a convenience for patients without having to drive or find transportation to a rehabilitation center, as well as reduce possible COVID-19 exposure in a setting with many people.

Stage I of the VNS-REHAB At-Home study includes (ACUTE):

* screening and consent

* pre-therapy baseline evaluation (prior to the start of therapy)

* Paired VNS™ for moderate to severe upper limb motor deficits will be provided in the patient's home by a therapist. Therapy length depends on scheduling between the therapist and subject for the subject's convenience. The intent is that 36 hours of in-home time will be provided over the study duration in two (2) or more visits per week. On days without the therapist-led rehabilitation, subjects will do therapist-prescribed functional activities on their own with magnet-activated VNS (self-activated VNS).

* Therapy assessments: performed after 12, 24, and 36 hours of therapist time in the subject's home.

Stage II includes (Long-Term):

* Therapy assessments at 3, 12, and 24 months after completion of 36 hours of therapist visit duration.

* Ongoing self-administration of at-home VNS during therapist-prescribed activities and rehabilitation outside of therapy visit duration.

* subjects will exit the study after their two-year visit.

Study Timeline

• Study First Submitted: 2023-01-10
• Study First Submitted QC: 2023-01-10
• Study First Posted: 2023-01-19
• Study Start: 2023-06-01
• Status Verified: 2024-06
• Last Update Submitted: 2024-06-13
• Last Update Posted: 2024-06-17
• Primary Completion: 2025-12-31
• Study Completion: 2028-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• Patient implanted or scheduled to be implanted commercially with the Vivistim System.
• Patient assessed as able to receive therapy in their home.

Exclusion Criteria

• Patient aged 18 or younger.
• Pregnant women

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Vivistim	Vivistim System	All subjects will be commercially implanted with the Vivistim System® after an ischemic stroke prior to Study treatment.

Primary Outcome Measures

Name	Time	Method
In-Home therapist time	within 18 weeks (after 36 hours of therapy)	The primary endpoint is to demonstrate that at least 24 hours of in-home therapist time occurs within an 18-week period (success criteria of 24 hours or more).

Secondary Outcome Measures

Name	Time	Method
Change in Fugl-Meyer (FMA)	within 18 weeks (after 36 hours of therapy)	Change in the FMA assessment measure compared to baseline

Trial Locations

Locations (1)

Moxie OT; 🇺🇸 Chicago, Illinois, United States